<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819959</url>
  </required_header>
  <id_info>
    <org_study_id>MIRACLE II</org_study_id>
    <nct_id>NCT03819959</nct_id>
  </id_info>
  <brief_title>Metabolomics Study on Intensive Care Acquired Muscle Weakness in Polytrauma</brief_title>
  <acronym>MIRACLE II</acronym>
  <official_title>Metabolomics Pilot Study on Intensive Care Acquired Muscle Weakness in Polytrauma (MIRACLE-II Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this mono-center pilot trial, polytrauma patients admitted to intensive care will be
      included. Investigators are going to take blood and muscle samples at respecified time points
      to do metabolic, histological and molecular testing.

      Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW
      (intensive care unit acquired weakness) and (2) identify metabolic components who are
      responsible for ICUAW or can be used as marker for ICUAW.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Blood Metabolome will be isolated from blood samples. All samples will be screened for changes in the blood metabolome during muscle wasting (i.e. Intensive Care Unit Acquired Weakness) using mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle histology</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Immunohistochemistry will be done in muscle samples. All samples will be screened for changes in the muscular structure and correlation with blood metabolome changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphoproteomics</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of muscular changes (i.e. Intensive Care Unit Acquired Weakness (ICUAW)) and correlation with blood metabolome changes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify possible predictors of muscle wasting in the blood metabolome at ICU admission</measure>
    <time_frame>a median of 14 days</time_frame>
    <description>Identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Metabolomics</condition>
  <condition>Critical Care</condition>
  <condition>Critical Illness</condition>
  <condition>Critical Illness Myopathy</condition>
  <condition>Critical Illness Polyneuropathy</condition>
  <condition>Intensive Care (ICU) Myopathy</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Intensive Care Patients</arm_group_label>
    <description>Polytrauma patients who have been admitted to intensive care</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood

        -  Skeletal muscle biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        polytrauma patients who are admitted to intensive care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute polytrauma patient

          -  age ≥ 18 years old

          -  expected intensive care stay ≥ 3 days

          -  American Society of Anesthesiologists classification I or II

        Exclusion Criteria:

          -  patient had received cardiopulmonary resuscitation

          -  limitation of therapy or comfort care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan J Schaller, MD, MHBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hennig Wackerhage, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan J Schaller, MD, MHBA</last_name>
    <phone>+49-89-4140-9635</phone>
    <email>s.schaller@tum.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manfred Blobner, MD</last_name>
    <phone>+49-89-4140-7206</phone>
    <email>m.blobner@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, School of Medicine, Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan J Schaller, MD</last_name>
      <phone>+49-89-4140-9635</phone>
      <email>s.schaller@tum.de</email>
    </contact>
    <contact_backup>
      <last_name>Manfred Blobner, MD</last_name>
      <phone>+49-89-4140-7206</phone>
      <email>m.blobner@tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan J Schaller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henning Wackerhage, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manfred Blobner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Schlegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 19, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universität München</investigator_affiliation>
    <investigator_full_name>Stefan Schaller</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pilot Trial</keyword>
  <keyword>Muscle Biopsy</keyword>
  <keyword>Blood Metabolome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

